Comparison of INCADRONATE (cas 138330-18-4) and alfacalcidol on increased bone turnover caused by ovariectomy in rats

Add time:08/23/2019    Source:sciencedirect.com

Mineral density of trabecular bone at the metaphyses of right tibiae was measured by peripheral quantitative computed tomography (pQCT) in ovariectomized rats. Bone mineral density (BMD) decreased dramatically in the 4 weeks following ovariectomy, suggesting that the method is sensitive enough to detect decreased bone mineral density within a short period. Orally administered INCADRONATE (cas 138330-18-4) dose dependently inhibited the decrease in trabecular bone mineral density induced by ovariectomy, as assessed 4 weeks after surgery. Significant inhibition was observed at doses of more than 0.3 mg/kg/day. Moreover, incadronate at doses of 1 mg/kg or more inhibited the increase in urinary deoxypyridinoline levels induced by ovariectomy, and although slightly increased serum intact parathyroid hormone (PTH) levels were observed, no significant alteration in serum calcium ion levels or urinary calcium excretion occurred. In contrast, while alfacalcidol inhibited the decrease in bone mineral density and the increase in urinary deoxypyridinoline levels at a dose of 300 ng/kg, it significantly lowered serum intact PTH levels and elevated serum free calcium levels as well as urinary calcium excretion. These results suggest that incadronate exerts its pharmacological effect (inhibition of bone resorption and increase in bone mass) by a mechanism different from that of alfacacidol.

We also recommend Trading Suppliers and Manufacturers of INCADRONATE (cas 138330-18-4). Pls Click Website Link as below: cas 138330-18-4 suppliers

Prev:From Lab to ClinicLack of Prophylactic Effect of INCADRONATE (cas 138330-18-4) on Skeletal Lesions Associated with Implants of Prostate Cancer☆
Next:Bisphosphonate INCADRONATE (cas 138330-18-4) prevents total gastrectomy-induced osteopenia in rats)